Category Archives: Biotech
Sequana Medical receives certification under MDR, the new European Medical Device Regulation
Below, we are re-publishing with permission the press-release issued by Sequana Medical on February 14, 2022 alfapump® is one of the first novel Class III active implantable medical devices to be certified Ghent, Belgium – 14 February 2022 – Sequana Medical NV (Euronext … Continue reading
Replicor publishes its REP 301-LTF study achieving durable functional cure of HDV and HBV, inactivation of cccDNA and elimination of integrated HBV DNA
Below, we are re-publishing with permission the press-release issued by Replicor Inc. on November 16, 2020 MONTREAL, November 16th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, … Continue reading
Clinical Accelerator announces collaboration with Noxopharm to advance idronoxil (NOX66), a novel treatment for COVID-19
Clinical Accelerator is pleased to announce a new collaboration with Noxopharm, a leading Australian drug development company. Noxopharm’s NOX66 therapy has received trial approval and is now in a Phase Ib, open-label trial by Clinical Accelerator in Eastern Europe. The … Continue reading
Clinical Accelerator to collaborate with Second Heart Assist on a Phase I study in Heart Failure
Clinical Accelerator and Second Heart Assist have recently entered into an exciting new collaboration, focused on developing a novel device for heart failure patients. An early feasibility trial will be conducted on Second Heart’s aortic stent based circulatory assist pump. … Continue reading
Clinical Accelerator announces collaboration with LARRK Bio Inc
Clinical Accelerator is excited to announce that it has entered into a collaboration with LARRK Bio Inc, a US based biotech start-up company focusing on skin health and dermatology. The company is currently in “stealth mode”. LARRK Bio is led … Continue reading
Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection
Below, we are re-publishing with permission the press-release issued by Replicor Inc. on March 09, 2020 MONTREAL, March 9, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, … Continue reading
The ongoing search for the better early-stage clinical trial location: a case study on Australia and Georgia
International biotech and medtech companies are constantly searching for optimal locations for their early stage and proof-of-concept clinical trials. An example of a location that has become increasingly popular is Australia. This is in large part due to the great … Continue reading
Clinical Accelerator collaborates with Thrombolytic Science International to study a tPA/mutant pro-urokinase dual regimen for thrombolysis in acute myocardial infarction
Clinical Accelerator, a full-service contract research organization, has entered into a collaboration with Thrombolytic Science International (TSI) to conduct a phase II randomised, multi-centre, open-label, parallel group mechanistic study using TSI’s dual treatment regimen in patients with ST elevation myocardial … Continue reading
Clinical Accelerator announces collaboration with Archivel Farma in a phase IIa Clinical Trial for RUTI®: a therapeutic vaccination against Multi-Drug Resistant Tuberculosis
Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Archivel Farma, for conducting a phase IIa clinical trial for their therapeutic vaccine RUTI® against multi-drug Resistant tuberculosis. The double-blind, randomized … Continue reading
Temple Therapeutics BV Announces Publication of Key Mechanism Data for Evitar™
Below, we are re-publishing with permission the press-release issued by Temple Therapeutics BV on the 10th of September 2018 Supports Evitar’s™ Novel Approach for Preventing Acute Tissue Fibrosis (Surgical Adhesions) Geleen, The Netherlands Temple Therapeutics BV (the “Company” or “Temple”)- September … Continue reading
Posted in Biotech, Clinical Accelerator
Leave a comment
clinicalaccelerator.com 
You must be logged in to post a comment.